Patients will receive ECT treatment as usual, but for this study if they choose to participate they will be randomized to receive bupropion (sustained release preparation 300 mg) (Wellbutrin ®), to be taken by mouth, in the morning (4 hours prior to ECT) on the day of ECT session 1 or session 2. There will be a one-time administration of bupropion at this dose with no discontinuation of medications that patient is already on. There will also be no washout period before bupropion administration or ECT.